TrialInvestigational new drugs2019

A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.

Inkeun Park et al.PubMed ↗Publisher ↗

No numbers read from the abstract.